NASDAQ · DMRA
Damora Therapeutics, Inc.
$22.01+$0.40 (+1.85%)
Damora Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 42.58% below the high.
Loading market information…
NASDAQ · EVGN · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Evogene Ltd.’s quoted price sits in the lower half of its reported 52-week range, 70.74% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Evogene Ltd.’s next earnings report is currently expected on Nov 19, 2026, with estimated earnings per share of -$0.19. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Evogene Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 21, 2025 |
| -$0.38+39.2% vs estimate |
| $2.44M+25.82% vs estimate |
| Q4 2024 | Mar 6, 2025 | $0.06+108.33% vs estimate | $1.61M-67.78% vs estimate |
|---|
| Q3 2024 | Nov 21, 2024 | -$1.31-29.7% vs estimate | $1.74M-52.0% vs estimate |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $2.15.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$22.01+$0.40 (+1.85%)
Damora Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 42.58% below the high.
$5.19-$0.06 (-1.14%)
Cingulate Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.35% below the high.
$1.23-$0.01 (-0.81%)
Dogwood Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.54% below the high.
$0.98-$0.01 (-1.01%)
Cocrystal Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.3% below the high.
$13.85-$3.97 (-22.28%)
Sensei Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.32% below the high.
$1.01+$0.01 (+1.0%)
Marker Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.94% below the high.
$0.29+$0.03 (+11.36%)
AEON Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.72% below the high.
$6.36-$0.22 (-3.34%)
Bolt Biotherapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.25% below the high.
